Cellectar Biosciences INC NEW financials
$1.82−0.55%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$7.2M | -$5.8M | -$5.7M | -$4.9M | -$6.0M | -$6.4M | -$20.5M | -$13.3M | -$13.7M | -$12.0M | -$12.5M | -$9.4M |
| Net income | -$6.9M | -$5.7M | -$5.3M | -$4.4M | -$5.4M | -$6.6M | -$2.4M | -$14.7M | -$919.4K | -$26.6M | -$7.9M | -$17.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.57 | $-1.33 | $-1.28 | $-1.41 | $-3.39 | $-4.30 | $-0.61 | $-12.13 | $-5.43 | $-27.30 | $-15.70 | $-46.50 |
| EBITDA | -$7.2M | -$5.9M | -$5.6M | -$4.8M | -$6.0M | -$6.3M | -$20.5M | -$13.3M | -$13.6M | -$11.9M | -$12.5M | -$9.4M |
| Operating cash flow | -$6.0M | -$4.8M | -$4.3M | -$4.3M | -$5.1M | -$9.4M | -$10.9M | -$9.2M | -$14.1M | -$13.4M | -$9.6M | -$8.1M |
| Free cash flow | -$6.0M | -$4.8M | -$4.4M | -$4.3M | -$5.1M | -$9.4M | -$11.0M | -$9.2M | -$14.2M | -$13.4M | -$9.9M | -$8.7M |
| Diluted shares | 12.2M | 4.2M | 4.1M | 3.2M | 1.6M | 1.5M | 3.9M | 1.3M | 1.2M | 1.0M | 0.5M | 0.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.0M | $8.3M | $13.2M | $12.6M | $11.0M | $13.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $36.6M | $11.1M | $15.0M | $14.6M | $13.7M | $16.0M |
| Total liabilities | $6.8M | $6.4M | $5.1M | $5.2M | $6.2M | $6.4M |
| Shareholders' equity | $29.9M | $3.3M | $8.5M | $8.0M | $7.5M | $8.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology